Skip to content

Released Oct 26, 2026, before the open

10-Q filed Oct 26, 2026, 26 days after period end · 0001628280-26-067276

Q3 2026 · 10-Q
Revenue—
Net Income-$25.37MN/M vs Q3 2025N/M vs Q2 2026
EPS Diluted-$0.35N/M vs Q3 2025N/M vs Q2 2026
Operating Income-$25,813,000N/M
Operating Cash Flowderived-$26,653,000N/M
Free Cash Flowderived-$26,653,000N/M

What the release said

Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights

Acumen Pharmaceuticals reported cash, cash equivalents and marketable securities of $78.6 million as of September 30, 2026, compared with $110.2 million as of June 30, 2026.2

Research and development expenses were $21.1 million for the quarter ended September 30, 2026, compared with $22.0 million a year earlier, and general and administrative expenses were $4.7 million, compared with $4.5 million.34

Loss from operations was $25.8 million for the quarter ended September 30, 2026, compared with $26.5 million, and net loss was $25.4 million, compared with $26.5 million.56

Cash, cash equivalents and marketable securities
$78.6 million As of Sept. 30, 20262
Cash, cash equivalents and marketable securities
$110.2 million As of June 30, 20262
Research and development expenses
$21.1 million Quarter ended Sept. 30, 2026, compared to $22.0 million for the quarter ended Sept. 30, 20253
General and administrative expenses
$4.7 million Quarter ended Sept. 30, 2026, compared to $4.5 million for the quarter ended Sept. 30, 20254
Loss from operations
$25.8 million Quarter ended Sept. 30, 2026, compared to $26.5 million for the quarter ended Sept. 30, 20255
Net loss
$25.4 million Quarter ended Sept. 30, 2026, compared to $26.5 million for the quarter ended Sept. 30, 20256
Thaler Agent · checked against the filing
Open the reading ›
The release

Same quarter

MetricQ3 2026Q3 2025Q3 2024Q3 2023
Net Income-$25.37M-$26.45M-$29.77M-$12.96M
EPS Diluted-$0.35-$0.44-$0.50-$0.24

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Acumen Pharmaceuticals, Inc. · CIK 1576885 · Engraved from SEC EDGAR